Northern Trust’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Northern Trust’s Portfolio BXRX Stock Details BXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-104	Closed	-$32K	–	4856
2021 Q4	$32K	Hold	104	–	–	﹤0.01%	4661
2021 Q3	$82K	Sell	104 -13	-11%	-$11.3K	﹤0.01%	4449
2021 Q2	$124K	Sell	117 -5	-4%	-$6.54K	﹤0.01%	4311
2021 Q1	$220K	Buy	122 +75	+160%	+$150K	﹤0.01%	4089
2020 Q4	$67K	Buy	47 +7	+18%	+$14.3K	﹤0.01%	4194
2020 Q3	$155K	Buy	40 +5	+14%	+$22.6K	﹤0.01%	3858
2020 Q2	$205K	Sell	35 -41	-54%	-$197K	﹤0.01%	3756
2020 Q1	$265K	Buy	76 +3	+4%	+$28.3K	﹤0.01%	3608
2019 Q4	$707K	Buy	+73	New	+$623K	﹤0.01%	3490

Other funds holding BXRX

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Northern Trust's BXRX Position: Q1 2022 in Review

Northern Trust sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q1 2022, closing a stake of 104 shares — an estimated $32K sold.

Northern Trust first reported a position in BXRX in Q4 2019 and held it in 9 quarters. The position peaked at $707K in Q4 2019. 19 funds tracked by Wall St. Rank hold BXRX as of Q1 2022.

Northern Trust reported no remaining Baudax Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Northern Trust sold 104 Baudax Bio, Inc. Common Stock shares in Q1 2022, an estimated $32K.
Northern Trust first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 9 quarters.
Northern Trust's Baudax Bio, Inc. Common Stock position peaked at $707K in Q4 2019.
19 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q1 2022.

Based on Northern Trust's 13F filing for Q1 2022, filed 13 May 2022.